<DOC>
	<DOCNO>NCT00445458</DOCNO>
	<brief_summary>The purpose study learn whether safe effective administer HKI-272 ( neratinib ) combination paclitaxel patient breast cancer .</brief_summary>
	<brief_title>A Phase 1/2 Study HKI-272 ( Neratinib ) Combination With Paclitaxel ( Taxol ) Subjects With Solid Tumors Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion part clinical trial : Good performance status Normal ejection fraction Adequate cardiac , kidney , liver function Adequate blood count At least one measurable target lesion Negative pregnancy test female subject Inclusion Criteria Part 1 Only : Pathologically confirm solid tumor curable available standard therapy Inclusion Criteria Part 2 Only : Pathologically confirm breast cancer HER2 positive tumor Prior treatment Herceptin Exclusion criterion part clinical trial : Major surgery , radiotherapy , chemotherapy investigational agent within two week treatment day 1 Subjects bone skin site disease Active central nervous system metastases Significant cardiac disease dysfunction Significant gastrointestinal disorder Inability unwillingness swallow HKI272 capsule Prior exposure HKI272 HER2 target agent , except trastuzumab ( Part 2 ) . Prior lapatinib permit arm B part 2 . Treatment taxane within 3 month treatment day 1 Grade 2 great motor sensory neuropathy Pregnant breast feed woman Known hypersensitivity paclitaxel Cremophor EL Prior treatment anthracyclines cumulative dose &gt; 400 mg/m^2 Any cancer within 5 year exception contralateral breast cancer , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin Exclusion Criteria Part 2 Only : More 1 ( arm A ) 3 ( arm B ) prior cytotoxic chemotherapy regimen metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>HKI-272</keyword>
	<keyword>neratinib</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>breast cancer</keyword>
</DOC>